The North America Clinical Chemistry Analyzers Market would witness market growth of 3.9% CAGR during the forecast period (2023-2030).
An important aspect contributing to the market's expansion is the introduction of novel items. The combined immunochemistry and clinical chemistry analyzers permit immunoassay-based testing, which significantly broadens the range of tests that can be carried out on a single system and cuts down on the time needed for quality inspections and maintenance of these analyzers. The integrated analyzers are available in various sample workloads and quantities (low, medium, and high) to meet the needs of the hospital and reference laboratories, which also helps to fuel demand and market expansion.
Clinical chemistry analyzers' technological advancements have made it possible to test more people and have enabled the early diagnosis of disease as well as specialized diagnoses in the fields of oncology, gynecology, and endocrinology. Advanced modeling and parameter estimates, greater resolution, better pattern recognition, artificial intelligence, and computer-assisted interpretation are some of the developments.
The rising demand for early diagnoses is further propelling the market's expansion in the North American region. For instance, the Canadian Cancer Society's 2021 study estimates that there were roughly 229,200 new instances of cancer identified in Canada that year. Additionally, 628 Canadians are receiving cancer diagnoses daily on average, with future projections indicating an increase in this number. The most common cancers in Canada (aside from non-melanoma skin cancer), according to the same survey, are breast, colorectal, lung, and prostate cancer. New, cutting-edge items are being introduced to the market by the leading manufacturers. Therefore, the market will expand rapidly in North America due to all the aforementioned factors.
The US market dominated the North America Clinical Chemistry Analyzers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,953.3 million by 2030. The Canada market is experiencing a CAGR of 6.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, Research Laboratories & Institutes, and Others. Based on Test Type, the market is segmented into Basic Metabolic Panel, Renal Profile, Liver Panel, Lipid Profile, Thyroid Function Panel, Electrolyte Panel, and Specialty Chemical Tests. Based on Product, the market is segmented into Reagents, Analyzers, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Clinical Chemistry Analyzers Market is Projected to reach USD 16.1 Billion by 2030, at a CAGR of 5.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Inc., Siemens Healthineers AG (Siemens AG), Horiba Ltd., Sysmex Corporation, Hitachi, Ltd., EKF Diagnostics Holdings plc and Ortho-Clinical Diagnostics, Inc. (QuidelOrtho Corporation).
By End User
By Test Type
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 